Pfizer: pediatric drug fails to meet primary endpoint
(CercleFinance.com) - Pfizer said that its drug Revatio has failed to meet its primary endpoint in a trial on newborns with persistent pulmonary hypertension.
The Phase 3 study that was designed to assess the efficacy and the safety of the intravenous drug when added to inhaled nitric oxide did not meet its primary efficacy endpoint, Pfizer said.
Treatment did not result in a statistically significant reduction in treatment failure rate or time on inhaled nitric oxide compared to treatment with inhaled nitric oxide alone, it said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Phase 3 study that was designed to assess the efficacy and the safety of the intravenous drug when added to inhaled nitric oxide did not meet its primary efficacy endpoint, Pfizer said.
Treatment did not result in a statistically significant reduction in treatment failure rate or time on inhaled nitric oxide compared to treatment with inhaled nitric oxide alone, it said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.